TY - JOUR
T1 - Synthesis and biological evaluation of Nα-(4-amino-4-deoxy-10-methylpteroyl)-DL-4,4-difluoroornithine
AU - Tsukamoto, Takashi
AU - Haile, William H.
AU - McGuire, John J.
AU - Coward, James K.
PY - 1996/6/21
Y1 - 1996/6/21
N2 - N α-(4-Amino-4-deoxy-10-methylpteroyl)-DL-4,4-difluoroornithine (AMPte-DL-4,4-F2Orn, 4) was synthesized and evaluated as an inhibitor of human folylpoly-γ-glutamate synthetase (FPGS), dihydrofolate reductase (DHFR), and cell growth. Synthesis of 4 involved the use of a protected form of DL-4,4-difluoroornithine 9 which was derived from DL-4,4-difluoroglutamic acid. Biological activities of 4 were compared directly to those of the corresponding nonfluorinated compound Nα-(4-amino-4-deoxy-10-methylpteroyl)-L-ornithine (AMPte-L-Orn, 3). Although the fluorinated analogue is a potent inhibitor of DHFR, it is a poor inhibitor of FPGS. However, the compound is transported across the cell membrane and inhibits cell growth, presumably due to the inhibition of DHFR. The data obtained with the fluorinated analogue are in contrast to those of the corresponding nonfluorinated compound 3, which is a potent inhibitor of both FPGS and DHFR but shows very low cytotoxicity due to poor transport.
AB - N α-(4-Amino-4-deoxy-10-methylpteroyl)-DL-4,4-difluoroornithine (AMPte-DL-4,4-F2Orn, 4) was synthesized and evaluated as an inhibitor of human folylpoly-γ-glutamate synthetase (FPGS), dihydrofolate reductase (DHFR), and cell growth. Synthesis of 4 involved the use of a protected form of DL-4,4-difluoroornithine 9 which was derived from DL-4,4-difluoroglutamic acid. Biological activities of 4 were compared directly to those of the corresponding nonfluorinated compound Nα-(4-amino-4-deoxy-10-methylpteroyl)-L-ornithine (AMPte-L-Orn, 3). Although the fluorinated analogue is a potent inhibitor of DHFR, it is a poor inhibitor of FPGS. However, the compound is transported across the cell membrane and inhibits cell growth, presumably due to the inhibition of DHFR. The data obtained with the fluorinated analogue are in contrast to those of the corresponding nonfluorinated compound 3, which is a potent inhibitor of both FPGS and DHFR but shows very low cytotoxicity due to poor transport.
UR - http://www.scopus.com/inward/record.url?scp=0029934297&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0029934297&partnerID=8YFLogxK
U2 - 10.1021/jm960046w
DO - 10.1021/jm960046w
M3 - Review article
C2 - 8691451
AN - SCOPUS:0029934297
SN - 0022-2623
VL - 39
SP - 2536
EP - 2540
JO - Journal of Medicinal Chemistry
JF - Journal of Medicinal Chemistry
IS - 13
ER -